Rodrigo Vazquez Guillamet

Medicine & Life Sciences

1. Lung Transplantation 100%
2. Lung 69%
3. Chronic Obstructive Pulmonary Disease 51%
4. Tissue Donors 34%
5. Mortality 27%
6. Transplants 26%
7. Infections 22%
8. Transplant Recipients 20%
9. Primary Graft Dysfunction 17%
10. Chronic Bronchitis 17%
11. Transplantation 14%
12. Smokers 14%
13. Survival 12%
14. Cohort Studies 11%
15. Hamman-Rich Syndrome 11%
16. Hospital Rapid Response Team 11%
17. Anti-Bacterial Agents 11%
18. Bacteremia 10%
19. Extravascular Lung Water 10%
20. Ehrlichiosis 10%
21. Comorbidity 10%
22. Healthcare-Associated Pneumonia 10%
23. Clinical Decision Rules 10%
24. Critical Illness 10%
25. Abatacept 10%
26. Candidemia 9%
27. Cefepime 9%
28. Obstructive Lung Diseases 9%
29. Tazobactam Drug Combination Piperacillin 9%
30. Thorax 9%
31. Interleukin-6 Receptors 9%
32. Terminal Care 9%
33. Septic Shock 9%
34. Pneumonia 9%
35. Tobacco Products 9%
36. Coronavirus 9%
37. Antilymphocyte Serum 9%
38. Interstitial Lung Diseases 9%
39. Pseudomonas 9%
40. Skilled Nursing Facilities 8%
41. Meropenem 8%
42. Water-Electrolyte Balance 8%
43. Critical Care 8%
44. Connective Tissue Diseases 8%
45. Smoke 8%
46. Immunocompromised Host 8%
47. Artificial Respiration 8%
48. Methicillin-Resistant Staphylococcus aureus 8%
49. Microbial Drug Resistance 8%
50. Electronic Health Records 8%